Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 TCR Gene Therapy: Challenges, Opportunities, and Future Directions.

Literature DB >> 33271744

TCR Gene Therapy: Challenges, Opportunities, and Future Directions.

Hans J Stauss¹, Maxine G B Tran².

Abstract

Adoptive immunotherapy with gene-engineered T cells has provided new treatment options for cancer patients [...].

Entities: CellLine Disease Gene Species

Mesh：

Substances：

Year: 2020 PMID： 33271744 PMCID： PMC7760667 DOI： 10.3390/cells9122567

Source DB: PubMed Journal: Cells ISSN： 2073-4409 Impact factor: 6.600

14 in total

1. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.

Authors: Ravit Oren; Moran Hod-Marco; Maya Haus-Cohen; Sharyn Thomas; Dan Blat; Nerri Duvshani; Galit Denkberg; Yael Elbaz; Fabrice Benchetrit; Zelig Eshhar; Hans Stauss; Yoram Reiter
Journal: J Immunol Date: 2014-10-31 Impact factor: 5.422

2. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.

Authors: Sharyn Thomas; Shao-An Xue; Charles R M Bangham; Bent K Jakobsen; Emma C Morris; Hans J Stauss
Journal: Blood Date: 2011-05-23 Impact factor: 22.113

Review 3. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.

Authors: Jan A Rath; Caroline Arber
Journal: Cells Date: 2020-06-18 Impact factor: 6.600

Review 4. T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road.

Authors: Michael D Crowther; Inge Marie Svane; Özcan Met
Journal: Cells Date: 2020-06-30 Impact factor: 6.600

Review 5. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.

Authors: Fabio Morandi; Mahboubeh Yazdanifar; Claudia Cocco; Alice Bertaina; Irma Airoldi
Journal: Cells Date: 2020-07-22 Impact factor: 6.600

Review 6. The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses.

Authors: Diana Campillo-Davo; Donovan Flumens; Eva Lion
Journal: Cells Date: 2020-07-18 Impact factor: 6.600

Review 7. Orthotopic T-Cell Receptor Replacement-An "Enabler" for TCR-Based Therapies.

Authors: Kilian Schober; Thomas R Müller; Dirk H Busch
Journal: Cells Date: 2020-06-01 Impact factor: 6.600

8. MHC Class I-Restricted TCR-Transgenic CD4⁺ T Cells Against STEAP1 Mediate Local Tumor Control of Ewing Sarcoma In Vivo.

Authors: Sebastian J Schober; Melanie Thiede; Hendrik Gassmann; Carolin Prexler; Busheng Xue; David Schirmer; Dirk Wohlleber; Stefanie Stein; Thomas G P Grünewald; Dirk H Busch; Guenther H S Richter; Stefan E G Burdach; Uwe Thiel
Journal: Cells Date: 2020-06-29 Impact factor: 6.600

Review 4. Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.

Authors: Nirmala Tilija Pun; Chul-Ho Jeong
Journal: Pharmaceuticals (Basel) Date: 2021-05-16

4 in total

TCR Gene Therapy: Challenges, Opportunities, and Future Directions.

1. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.

2. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.

Review 3. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.

Review 4. T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road.

Review 5. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.

Review 6. The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses.

Review 7. Orthotopic T-Cell Receptor Replacement-An "Enabler" for TCR-Based Therapies.

8. MHC Class I-Restricted TCR-Transgenic CD4⁺ T Cells Against STEAP1 Mediate Local Tumor Control of Ewing Sarcoma In Vivo.

Review 9. Engineering CD4+ T Cells to Enhance Cancer Immunity.

Review 10. Breaking Bottlenecks for the TCR Therapy of Cancer.

Review 1. T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy.

Review 2. Gene Edited T Cell Therapies for Inborn Errors of Immunity.

Review 3. Anaplastic lymphoma kinase-special immunity and immunotherapy.

Review 4. Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.

TCR Gene Therapy: Challenges, Opportunities, and Future Directions.

1. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.

2. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.

Review 3. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.

Review 4. T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road.

Review 5. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.

Review 6. The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses.

Review 7. Orthotopic T-Cell Receptor Replacement-An "Enabler" for TCR-Based Therapies.

8. MHC Class I-Restricted TCR-Transgenic CD4+ T Cells Against STEAP1 Mediate Local Tumor Control of Ewing Sarcoma In Vivo.

Review 9. Engineering CD4+ T Cells to Enhance Cancer Immunity.

Review 10. Breaking Bottlenecks for the TCR Therapy of Cancer.

Review 1. T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy.

Review 2. Gene Edited T Cell Therapies for Inborn Errors of Immunity.

Review 3. Anaplastic lymphoma kinase-special immunity and immunotherapy.

Review 4. Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.

8. MHC Class I-Restricted TCR-Transgenic CD4⁺ T Cells Against STEAP1 Mediate Local Tumor Control of Ewing Sarcoma In Vivo.